Rising Use of Chemotherapy and Radiotherapy in the Cancer Treatment Drives the Growth of the India Xerostomia Therapeutics Market

In India, the xerostomia therapeutic market comprises various products and treatments that cater to individuals experiencing dry mouth symptoms. These include:

Access Full Report @ https://www.databridgemarketresearch.com/zh/reports/india-xerostomia-therapeutics-market

Saliva Substitutes: These are artificial saliva formulations designed to mimic the properties of natural saliva. These products aim to provide temporary relief from dry mouth symptoms by moisturizing and lubricating the oral cavity.

Saliva Stimulants: These are medications or formulations that stimulate the production of saliva. These products work by activating the salivary glands, increasing the saliva flow, and relieving the dry mouth sensation.

Oral Moisturizers: These are specially formulated products that help maintain oral moisture and alleviate dry mouth symptoms. They often come in the form of sprays, gels, or mouth rinses, providing temporary relief, and hydration.

Data Bridge Market Research analyzes that the India Xerostomia Therapeutics Market is expected to grow at a CAGR of 5.1% in the forecast period from 2023 to 2030 and is expected to reach USD 25.20 million by 2030. The rise in the prevalence of xerostomia is expected to propel the market growth.

Key Findings of the Study

Advancements in Pharmaceutical Research and Development

The pharmaceutical sciences represent an evolving and highly dynamic field, and two overreaching trends show an increased effort to develop biologic-based drugs and create more specific or targeted drug delivery techniques. Some recent developments are the development of spatial aggregation propensity for detecting protein aggregation, advancement in drug-delivery technologies involving microencapsulation and Nanocoatings, and tools to understand the risk of nanomaterials in drug-delivery systems.

For instance,

• In February 2023, according to the information provided by ANI news, the pharma industry in India is ranked third in the world for pharmaceutical production by volume, covering 20 percent of the global supply. The statistics configured by IBEF (Indian Brand Equity Foundation) state that the domestic pharmaceutical market stood at USD 42 billion in 2021

Report Scope and Market Segmentation

Segment Analysis

The India xerostomia therapeutics market is segmented into six notable segments based on product type, type, mode of purchase, population, end user, and distribution channel.

• On the basis of product type, the market is segmented into saliva substitutes, drugs, salivary pen, and others. In 2023, the saliva substitutes segment is expected to dominate the market with a 61.84% market share.

In 2023, the saliva substitutes of product type segment is expected to dominate the market due to a rise in the prevalence of xerostomia

In 2023, the saliva substitutes segment is expected to dominate the market due to a rise in the prevalence of xerostomia.

• On the basis of type, the market is segmented into true xerostomia and pseudo xerostomia or symptomatic xerostomia. In 2023, the true xerostomia segment is expected to dominate the market with a 70.75% market share.
• On the basis of mode of purchase, the market is segmented into prescription (Rx) and Over the Counter (OTC). In 2023, the prescription (Rx) segment is expected to dominate the market with a 74.88% market share.
• On the basis of population type, the market is segmented into geriatric and adults. In 2023, the geriatric segment is expected to dominate the market with a 71.93% market share.
• On the basis of end user, the market is segmented into dental clinics, hospitals, specialty clinics, and home care. In 2023, the dental clinics segment is expected to dominate with a 31.77% market share.

In 2023, the dental clinics segment is projected to hold the largest share of end user segment in the market

In 2023, the dental clinics segment is expected to dominate due to a rise in the number of various facilities provided in dental clinics and is expected to dominate .

• On the basis of distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online sales. In 2023, the retail pharmacies segment is expected to dominate the market with a 44.02% market share.

Major Players

Data Bridge Market Research recognizes the following companies as the major market players in the India xerostomia therapeutics market that include Haleon Group of Companies. (U.K.), Colgate-Palmolive Company. (U.S.), Sun Pharmaceutical Industries Ltd.(India), 3M.(U.S.), Alish Life Saving Impex Private Limited.(India), Saliwell Ltd.(Israel), GC Corporation(Japan), and ICPA Health Products Ltd(India) among others.

Market Developments

• In March 2021, Colgate-Palmolive and Philips started a long-term collaboration to bring the oral care benefits of electric toothbrushes to people in Latin America. This has helped the company to expand its business.
• In January 2022, Colgate-Palmolive Company and 3Shape partnered to introduce the Colgate Illuminator, an exclusive, tailored-to-patient teeth whitening tool, to dental clinics across the U.S. The new tool will enable more accurate consultations and deliver an improved patient experience. This has helped the company to expand their global presence.
• In January 2023, Sun Pharmaceutical Industries Limited announced that it has acquired three brands viz. Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg), Phlogam (Trypsin BP 48 mg, and Bromelain 90 mg & Rutoside Trihydrate 100 mg) from Aksigen Hospital Care (“Aksigen”), a Mumbai based research-driven healthcare entity with more than two decades of experience in the healthcare field. This has helped the company to expand their business.
• In March 2023, Sun Pharmaceutical Industries Limited announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia areata. This has helped the company to expand its business.
• In April 2023, Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries has launched a novel ophthalmology treatment, CEQUA, in India for patients who have Dry Eye Disease (DED) with inflammation, a commonly occurring condition. CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology. This has helped the company to expand its product portfolio.

Regional Analysis

Geographically, the country covered in the India xerostomia therapeutics market report is India.

As per Data Bridge Market Research analysis

The India xerostomia therapeutics market is expected to grow at a CAGR of 5.1% due to the rising prevalence of xerostomia and rising chemotherapy and radiotherapy.

For more detailed information about the Produced water treatment market, click here – https://www.databridgemarketresearch.com/zh/reports/india-xerostomia-therapeutics-market